An RNA cancer vaccine is a therapeutic platform that trains the immune system to recognize and attack cancer cells by delivering messenger RNA encoding tumor-associated antigens, prompting the patient’s own cells to produce these proteins and trigger a targeted immune response.
This molecular approach represents a fundamental shift in oncology. Unlike chemotherapy or radiation, which directly kill malignant cells, RNA vaccines harness the body’s immune surveillance to selectively eliminate tumor tissue while sparing healthy cells. The technology emerged from decades of immunotherapy research but gained unprecedented …